Today: December 16, 2017, 10:06 am
  
Business

EDHEC welcomes Fidelity's announcement on the introduction of performance-based fees but considers that it is possible to do better

PR-Inside.com: 2017-10-05 15:43:01
EDHECScientificbeta

Fidelity International's announcement on October 3 that it was implementing a fee scheme that aims to adapt fees to performance is a very good response to asset owners' and consultants' excessive focus on price reductions alone.

EDHEC welcomes the fact that by linking fees to performance, Fidelity, like Allianz Global Investors and Alliance Bernstein before them, allow investors to question other aspects of the investment management offering than the price aspect alone, especially the robustness of performance, and in the same way the quality of the investment management offerings.

Exclusively focusing on price favours a genuine phenomenon of adverse selection, which leads to a loss of interest in the quality of products, and therefore incites operators to neglect quality and reduce their research and risk control fees in order to win the price war. This phenomenon of adverse selection, which has given rise to extensive academic research, notably that of George Akerlof, who was awarded the Nobel Prize in 2001 for his research, is particularly present in the new forms of passive investment, especially smart beta, where the confusion between simulated track record and live track record maintained by the actors involved prevents investors from easily distinguishing between good and bad offerings.

Reacting to Fidelity International's announcement, Professor Noël Amenc, Associate Dean for Business Development with EDHEC Business School and CEO of ERI Scientific Beta, indicates that, "In the coming weeks ERI Scientific Beta will update its variable fee scheme, which allows investors to pay zero fees if the Scientific Beta multi-factor multi-strategy index chosen does not outperform the reference index over the year. We think that in all logic Fidelity should also reduce their fees to zero if they underperform the benchmark, which is not the case in their fulcrum fees proposal."

ERI Scientific Beta's variable scheme, which was launched in May 2016, is part of its response to the excessive attention that investors pay to fees, to the detriment of an assessment of the quality of performance and its out-of-sample robustness. Noël Amenc adds, "We are currently witnessing a highly worrying phenomenon of in-sample optimisation of the performance and factor intensity of smart beta indices to the detriment of their robustness, with a fairly cynical strategy of "sell and forget." Even though smart beta indices sometimes have live track records of more than 10 years, index promoters prefer to calculate future expected returns rather than showing their historical performance. By linking fees to performance, investors have the possibility of putting pressure on the quality of the products that are offered to them."


As part of its policy of transferring know-how to the industry, EDHEC-Risk Institute has set up ERI Scientific Beta. ERI Scientific Beta is an original initiative which aims to favour the adoption of the latest advances in smart beta design and implementation by the whole investment industry. Its academic origin provides the foundation for its strategy: offer, in the best economic conditions possible, the smart beta solutions that are most proven scientifically with full transparency of both the methods and the associated risks.
ERI Scientific Beta, 1 George Street, #15-02, Singapore 049145. For further information, please contact: contact@scientificbeta.com, Web: www.scientificbeta.com.

Press_release_Fidelity_performance_fees



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: EDHEC-Risk Institute via Globenewswire




# 802 Words
Related Articles
More From The Author
Teva Announces tomy’s Award Winner at Oncology [..]
Teva Pharmaceuticals Europe BV, (NYSE and TASE: TEVA) announced the winner of the tomy’s (Teva’s Orphan hematological Malignancies [..]
Winter Business with Yourtyres.co.uk: Make the Most [..]
For car companies and tyre dealers, the autumn changeover season is one of the best times of year for generating [..]
Invitation to a presentation of the Momentum [..]
Momentum Group will publish its Interim Report for the second quarter of the financial year 2017/18 on Friday, 27 October [..]
SkyKick Expands European Operations to Support Global [..]
Doubles number of European employees and moves into a larger Amsterdam-based European headquarters to support partner growth in [..]
SpareBank 1 SMN : Possible New senior [..]
SpareBank 1 SMN has mandated Nordea Markets and SpareBank 1 Markets to investigate the opportunity to issue a new bond in [..]
 
More From Business
This Week, Woo your Friends with Beautiful [..]
The company can provide flowers and cakes to any place around the Adipur or Vadodara town in just 3 to [..]
Eram Scientific Wins India’s First-ever Swachh Bharat [..]
Dubai, United Arab Emirates, December 15, 2017: Eram Group, a diversified business conglomerate headquartered in Dubai, announced [..]
Hire A Bookaskip Mini Skip For That [..]
As we all know, December is ‘party month’ and, although we all love a good party, we are not so [..]
Cirtek Holdings Philippines Corp Holds Its First-Ever [..]
SAN FRANCISCO, CA, Dec 8, 2017 - (ACN Newswire) - All-Asia institutional equities broker Decker & Co. hosted Cirtek Holdings [..]
Business of Intellectual Property (BIP Asia) Forum [..]
Industry Experts Gather in Hong Kong to Promote IP and Innovation HONG KONG, Dec 7, 2017 - (ACN Newswire) - [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.